April 20, 2015
OXFORD, UK - 16 April 2015 - PsiOxus Therapeutics Ltd. (PsiOxus), an oncolytic immunoncology company, has announced that it will present data highlighting the progress of its next generation Antibody Armed EnAd" (AbEnAd) anti-cancer therapeutic platform at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia, PA April 19-22, 2015. AbEnAd is...
Phase I Study Results Confirming Intravenous Delivery Profile and Repeated Dosing Leads to Expansion of the Clinical Programme into New Indications


DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge